MedPath

A Salivary miRNA Diagnostic Test for Autism

Completed
Conditions
Autism Spectrum Disorder
Developmental Delay
Interventions
Other: Salivary collection
Other: Vineland Adaptive Behavior Scale-III Assessment
Other: Medical history questionaire
Other: Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)
Other: Mullen Scales of Early Learning
Registration Number
NCT02832557
Lead Sponsor
State University of New York - Upstate Medical University
Brief Summary

The goal of this study is to validate a panel of miRNAs that distinguish children with autism spectrum disorder (ASD) from their non-ASD peers with a positive MCHAT-R. These biomarkers may allow earlier diagnosis of autism, allowing earlier service, and also help us to understand some of the changes in the brains of autistic children.

Detailed Description

The central aim of this project is to validate a panel of expressed microRNA (miRNA) in the saliva of children identified at risk for developing ASD by the MCHAT-R. Further, this study aims to assess the value of the current panel as an adjunctive test that may increase specificity of MCHAT-R positive results, or affirm clinical diagnoses alongside the ADOS or other objective assessments.

The primary endpoints of this study are as follows:

1. Evaluate the diagnostic ability (sensitivity and specificity) of the current a salivary microtranscriptome panel for distinguishing children with ASD from their non-ASD peers.

2. Assess stability of the salivary microtranscriptome diagnosis over time, and interrogate longitudinal microtranscriptome levels relative to neuropsychological measures.

Secondary endpoints are the identification of microtranscriptome features whose concentrations correlate with ASD endophenotypes.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
998
Inclusion Criteria
  • Age at enrollment: 24 months to 48 months (inclusive)
  • MCHAT-R score of 3 or greater
  • Parent/guardian must be fluent in spoken English (required to complete study specific questionnaires etc)
Exclusion Criteria
  • confounding neurological (i.e. cerebral palsy, epilepsy), sensory (i.e. auditory or visual) impairments, and feeding tube dependence.
  • history of extreme pre-term birth (< 32 weeks gestation)
  • wards of the state
  • Autistic subjects with known syndromic autism (attributed to a known genetic mutation)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
MCHAT-R PositiveVineland Adaptive Behavior Scale-III AssessmentChildren identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
MCHAT-R PositiveSalivary collectionChildren identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
MCHAT-R PositiveMedical history questionaireChildren identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
MCHAT-R PositiveAutism Diagnostic Observation Schedule -2nd edition (ADOS-2)Children identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
MCHAT-R PositiveMullen Scales of Early LearningChildren identified at risk for the development of autism spectrum disorder (ASD) by scoring a 3 or higher on the MCHAT-R. Participants should not have a history of extreme pre-term birth or underlying neurological disorders such as seizures or cerebral palsy.
Primary Outcome Measures
NameTimeMethod
Salivary miRNA profileat the time of collect (from 18m to 6 years of age)

Measures of miRNA abundance in saliva

Secondary Outcome Measures
NameTimeMethod
Measure of autistic behaviorAt time of enrollment (from 18m to 6 years of age)

Autism Diagnostic Observation Schedule (ADOS) Composite Score (Autism Group Only)

Measures of early intellectual developmentAt time of enrollment (from 18m to 6 years of age)

Mullen Scales of Early Learning

Measures of adaptive functionAt time of enrollment (from 18m to 6 years of age)

Vineland Adaptive Behavior Composite Score

Trial Locations

Locations (1)

SUNY Upstate Medical University

🇺🇸

Syracuse, New York, United States

© Copyright 2025. All Rights Reserved by MedPath